C-반응성 단백질 검사 시장 : 제품 유형별, 기술별, 검사 유형별, 검체 유형별, 최종 사용자별, 용도별 - 세계 예측(2026-2032년)

The C-Reactive Protein Testing Market was valued at USD 1.89 billion in 2025 and is projected to grow to USD 2.11 billion in 2026, with a CAGR of 12.95%, reaching USD 4.43 billion by 2032.

Understanding the clinical centrality and evolving utility of C-reactive protein testing across acute care, chronic disease management, and population health settings

C-reactive protein (CRP) testing occupies a vital intersection between clinical diagnostics and population health management, serving as a rapid biochemical indicator of systemic inflammation and a surrogate marker across a spectrum of acute and chronic conditions. In clinical practice, CRP assays inform diagnostic pathways for infection and inflammatory disorders, guide therapeutic monitoring in autoimmune disease, and contribute to cardiovascular risk stratification when high-sensitivity (hs-CRP) methods are employed. The evolution of testing modalities from centralized laboratory platforms to decentralized point-of-care solutions has expanded both clinical access and the contexts in which CRP results influence decision-making.

Technological advancement and shifting care models are reshaping clinician expectations about turnaround time, analytical sensitivity, and seamless integration with health information systems. Consequently, procurement teams and laboratory managers must evaluate CRP testing not solely on analytical performance but also on workflow compatibility, total cost of ownership, and interoperability with electronic medical records and laboratory information systems. As the clinical applications of CRP broaden, stakeholders across hospitals, outpatient clinics, and research environments are recalibrating how they incorporate CRP data into diagnostic algorithms and chronic disease management pathways.

How rapid decentralization, assay sensitivity improvements, and integrated data services are redefining the strategic value of CRP diagnostics in clinical care

The landscape for CRP testing is undergoing transformative shifts driven by technological innovation, evolving clinical guidelines, and the decentralization of diagnostics. Point-of-care analyzers are moving beyond basic qualitative outputs to provide quantitative, clinically actionable CRP values with rapid turnaround, enabling same-visit clinical decisions in both outpatient and emergency settings. Simultaneously, laboratory analyzers are increasing throughput and automation while reagent developers refine assay chemistries to enhance sensitivity and specificity, especially for hs-CRP applications relevant to cardiovascular risk assessment.

Data management and consulting services are growing in importance as stakeholders demand standardized reporting, quality control harmonization, and integration of CRP results into broader clinical decision support tools. Moreover, cross-disciplinary research linking inflammation markers to metabolic, oncologic, and infectious disease pathways is fueling novel clinical use cases that extend beyond traditional acute care diagnostics. In short, the market is shifting from a commodity perception of CRP assays to a value-driven model where analytical performance, workflow integration, and real-world clinical impact determine adoption.

Assessing the cumulative operational and supply chain consequences of 2025 US tariff measures on CRP testing procurement and manufacturing strategies

Recent tariff actions affecting imports into the United States in 2025 have created a complex overlay of trade-related considerations that influence supply chains and procurement strategies for CRP testing components and finished devices. Manufacturers that rely on cross-border sourcing for instruments, assay reagents, or critical consumables have encountered altered landed costs and extended lead times, prompting many to re-evaluate supply resiliency measures. In response, several upstream suppliers have accelerated dual-sourcing strategies and increased inventory buffers to mitigate disruption, with downstream laboratory customers adjusting procurement cadence to protect clinical continuity.

Beyond immediate cost and logistics effects, tariff-induced adjustments have influenced longer-term strategic decisions, including regional manufacturing footprint optimization and localized reagent production to reduce exposure to trade fluctuations. This shift has also heightened collaboration between diagnostic firms and contract manufacturers that possess domestic capabilities, thereby shortening supply chains and enhancing quality oversight. In parallel, purchasing groups and health systems are pursuing consolidated contracting models to secure more predictable terms and to leverage volume for better pricing stability. Overall, the cumulative impact has been to make supply chain flexibility and supplier transparency top priorities for organizations that rely on CRP testing.

Comprehensive segmentation analysis across product, technology, end user, application, test type, and sample type to illuminate clinical priorities and innovation pathways for CRP testing

A granular segmentation view reveals differentiated demand drivers and operational criteria across product, technology, end user, application, test type, and sample type that shape procurement and development priorities. From a product perspective, stakeholders evaluate laboratory analyzers and point-of-care analyzers under the instruments category with distinct expectations: centralized laboratory analyzers prioritize throughput and automation while point-of-care analyzers emphasize speed, portability, and ease of use. Reagents and kits are divided between CRP kits and hs-CRP kits, where assay sensitivity and lot-to-lot consistency affect clinical utility. Software and services encompass consulting offerings and data management software that support quality assurance, interoperability, and longitudinal data analytics.

Technology choices-whether ELISA, immunoturbidimetric approaches including latex-enhanced or turbidimetric variants, or nephelometry-affect assay precision, sample throughput, and compatibility with existing instrumentation. End-user contexts vary widely: academic and research institutes focus on assay flexibility and novel marker validation while clinics, which include both tier I and tier II facilities, prioritize rapid turnaround and ease of operation; diagnostic laboratories, subdivided into hospital-based and independent labs, balance throughput with assay cost-efficiency; hospitals, whether general or specialized, demand validated workflows and robust quality systems. Applications span diagnostics and monitoring across cancer, cardiovascular disease where clinicians differentiate between coronary heart disease and stroke risk contexts, diabetes screening interactions, and a broad set of infection and inflammatory disorders including autoimmune conditions as well as bacterial and viral infections. Test type considerations distinguish quantitative methods, with automated and manual test pathways, from semi-quantitative approaches such as immunophoresis and lateral flow tests, each informing clinical interpretation and point-of-care suitability. Finally, sample type decisions-between plasma, serum, and whole blood, and their subcategories such as EDTA or heparin plasma and capillary versus venous whole blood-determine pre-analytical workflows and accessibility in ambulatory or field settings. Taken together, these segmentation lenses clarify where incremental innovation, targeted commercialization, and operational investment can yield the greatest clinical and commercial returns.

How regional infrastructure, regulatory diversity, and care delivery models across major global regions determine CRP testing adoption pathways and supply strategies

Regional dynamics exert a profound influence on adoption patterns, supply chain planning, regulatory navigation, and clinical preferences for CRP testing across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical adoption is driven by integrated health systems and widespread laboratory infrastructure that support both centralized high-throughput testing and expansion of point-of-care services; reimbursement frameworks and clinical practice guidelines further shape where hs-CRP assays gain traction. Moving to Europe, Middle East & Africa, stakeholders contend with heterogeneous regulatory regimes and infrastructure variability; in many markets, harmonized standards coexist with pockets of strong centralized laboratory networks and growing demand for decentralized diagnostics, particularly in urban centers.

Asia-Pacific presents a dynamic mix of high-volume manufacturing capability, rapid technology adoption in urban healthcare hubs, and diverse end-user profiles ranging from large hospital systems to community clinics. Collectively, these regions present distinct challenges and opportunities for manufacturers and service providers seeking to optimize distribution, localized manufacturing, and regulatory strategies. Strategic entry or expansion plans should therefore align with each region's clinical practice patterns, procurement norms, and the maturity of laboratory networks to ensure sustainable uptake of CRP testing solutions.

Mapping the competitive ecosystem where instrument makers, reagent specialists, software vendors, and point-of-care innovators converge to define value in CRP diagnostics

Competitive dynamics in the CRP testing ecosystem are characterized by a mix of established diagnostic manufacturers, specialized reagent developers, software and data service providers, and nimble point-of-care innovators that together shape product availability, performance benchmarks, and service models. Leading instrument makers are extending platform interoperability to accommodate a broader range of assay chemistries while reagent specialists focus on improving assay stability and reducing pre-analytical variability. Concurrently, software vendors and consulting firms are enhancing data management capabilities to deliver automated quality control, trend analysis, and integration with electronic health records-functions that increasingly determine the value proposition for clinical laboratories and health systems.

Partnerships between instrumentation companies and third-party reagent suppliers remain common, and strategic alliances with contract manufacturers have increased to support flexible production and regional supply. New entrants are differentiating through point-of-care form factors, simplified workflows for non-laboratory personnel, and bundled service offerings that include remote connectivity and performance monitoring. For purchasers and decision-makers, vendor selection increasingly hinges on demonstrated clinical performance, regulatory compliance, post-market support, and the ability to provide end-to-end solutions that reduce implementation risk and operational complexity.

Actionable strategic priorities for diagnostic manufacturers and healthcare providers to accelerate CRP test performance, adoption, and supply resilience

Industry leaders seeking to strengthen market position and clinical impact should prioritize initiatives that balance innovation, supply resilience, and interoperability. First, investing in assay performance enhancements-particularly for hs-CRP sensitivity and reproducibility-will address unmet clinical needs in cardiovascular risk assessment and inflammatory disease monitoring. Second, expanding modular point-of-care platforms that integrate with laboratory information systems will facilitate broader adoption across outpatient and emergency settings, enabling same-visit clinical decisions and tighter care pathways.

Additionally, companies should diversify supply chains by developing regional manufacturing capabilities or partnering with domestic contract manufacturers to reduce exposure to trade volatility. Strategic collaborations with clinical networks and research institutions can accelerate real-world evidence generation and support guideline inclusion. Finally, embedding robust data management, remote monitoring, and post-market surveillance services into product offerings will provide customers with measurable quality assurance and long-term value, thereby strengthening commercial differentiation and customer retention.

Transparent, multi-source research methodology combining stakeholder interviews, clinical validation evidence, and technology performance assessments to inform actionable insights

The research underpinning this executive summary integrates primary stakeholder interviews, synthesis of peer-reviewed clinical literature, regulatory filings, and a structured assessment of technology performance characteristics. Primary engagement included discussions with clinical laboratory directors, procurement leaders, hospital clinicians, point-of-care program managers, and assay development scientists to capture real-world operational constraints and clinical decision drivers. Secondary sources comprised methodological reviews and assay validation studies to evaluate analytical trade-offs among ELISA, immunoturbidimetric, and nephelometric approaches.

Data synthesis prioritized methodological transparency: inclusion criteria for studies emphasized assay validation parameters, reproducibility metrics, and sample type comparability. Quality assurance assessments evaluated regulatory clearances, documented lot-to-lot consistency, and post-market performance reports when available. The analytical framework triangulated qualitative insights with technical performance characteristics to generate practical recommendations for product development, procurement, and clinical implementation strategies. Throughout, attention was given to pre-analytical variables and workflow integration, recognizing their outsized impact on clinical utility and operational adoption.

Closing synthesis on aligning assay performance, workflow integration, and supply flexibility to maximize clinical and operational value from CRP testing

In conclusion, C-reactive protein testing retains critical clinical relevance across acute care, chronic disease management, and research contexts, and its strategic importance is increasing as diagnostic paradigms shift toward rapid, decentralized, and data-integrated care models. The interplay between instrument capabilities, assay chemistry, data services, and regulatory environments determines how quickly and effectively CRP testing can be adopted in different care settings. As supply chain considerations and trade measures influence procurement dynamics, organizations must emphasize flexibility, vendor transparency, and localized supply options to maintain clinical continuity.

Looking ahead, the most impactful opportunities will arise where analytical performance improvements are coupled with seamless workflow integration and demonstrable clinical outcomes. Decision-makers should therefore align investments with use cases that deliver clear clinical value, ensure interoperability with health information systems, and prioritize collaborations that accelerate real-world evidence generation. By doing so, stakeholders can harness CRP testing not just as a laboratory assay but as a strategic diagnostic tool that supports better patient management and system-level efficiency.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. C-Reactive Protein Testing Market, by Product

• 8.1. Instruments
  • 8.1.1. Laboratory Analyzers
  • 8.1.2. Point-Of-Care Analyzers
• 8.2. Reagents & Kits
  • 8.2.1. Crp Kits
  • 8.2.2. Hs-Crp Kits
• 8.3. Software & Services
  • 8.3.1. Consulting Services
  • 8.3.2. Data Management Software

9. C-Reactive Protein Testing Market, by Technology

• 9.1. Elisa
• 9.2. Immunoturbidimetric
  • 9.2.1. Latex Enhanced
  • 9.2.2. Turbidimetric
• 9.3. Nephelometry

10. C-Reactive Protein Testing Market, by Test Type

• 10.1. Quantitative
  • 10.1.1. Automated Tests
  • 10.1.2. Manual Tests
• 10.2. Semi-Quantitative
  • 10.2.1. Immunophoresis Tests
  • 10.2.2. Lateral Flow Tests

11. C-Reactive Protein Testing Market, by Sample Type

• 11.1. Plasma
  • 11.1.1. Edta Plasma
  • 11.1.2. Heparin Plasma
• 11.2. Serum
• 11.3. Whole Blood
  • 11.3.1. Capillary Blood
  • 11.3.2. Venous Blood

12. C-Reactive Protein Testing Market, by End User

• 12.1. Academic & Research Institutes
• 12.2. Clinics
  • 12.2.1. Tier I Clinics
  • 12.2.2. Tier II Clinics
• 12.3. Diagnostic Laboratories
  • 12.3.1. Hospital-Based Labs
  • 12.3.2. Independent Labs
• 12.4. Hospitals
  • 12.4.1. General Hospitals
  • 12.4.2. Specialized Hospitals

13. C-Reactive Protein Testing Market, by Application

• 13.1. Cancer
• 13.2. Cardiovascular Diseases
  • 13.2.1. Coronary Heart Disease
  • 13.2.2. Stroke
• 13.3. Diabetes
• 13.4. Infection & Inflammatory Disorders
  • 13.4.1. Autoimmune Disorders
  • 13.4.2. Bacterial Infections
  • 13.4.3. Viral Infections

14. C-Reactive Protein Testing Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. C-Reactive Protein Testing Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. C-Reactive Protein Testing Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States C-Reactive Protein Testing Market

18. China C-Reactive Protein Testing Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. Abbott Laboratories, Inc.
• 19.6. Abcam PLC
• 19.7. Alere Inc.
• 19.8. Bio-Rad Laboratories, Inc.
• 19.9. bioMerieux SA
• 19.10. BODITECH MED, INC
• 19.11. CTK Biotech Inc.
• 19.12. Danaher Corporation
• 19.13. DiaSorin S.p.A.
• 19.14. Eurolyser Diagnostica GmbH
• 19.15. F. Hoffmann-La Roche Ltd.
• 19.16. Fujifilm Corporation
• 19.17. Getein Biotech, Inc.
• 19.18. HORIBA, Ltd.
• 19.19. Lumiradx Healthcare Private Limited
• 19.20. Merck KGaA
• 19.21. Ortho Clinical Diagnostics, LLC
• 19.22. Quest Diagnostics Incorporated
• 19.23. Randox Laboratories Ltd.
• 19.24. Roche Diagnostics International AG
• 19.25. SD Biosensor, Inc.
• 19.26. Sekisui Diagnostics
• 19.27. Siemens Healthineers AG
• 19.28. Thermo Fisher Scientific, Inc.
• 19.29. Trinity Biotech PLC